Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Mitral Valve Prolapse III: Nursing Management

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Baseline Neuroinflammation Stratifies TSPO-PET Response to Disease-Modifying Therapy in Multiple Sclerosis.

Annals of clinical and translational neurology·2026

Same author

The test-retest reproducibility of [<sup>11</sup>C]PK11195 positron emission tomography using Biograph Vision Quadra scanner.

EJNMMI research·2026

Same author

TSPO-PET-measurable neuroinflammation associates with information processing speed decline in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Same author

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.

Lancet (London, England)·2026

Same author

Authors reply to letter to the editor regarding "Selective serotonin reuptake inhibitor use during pregnancy and maternal depression: a nationwide birth cohort study on risks to the mother and the newborn".

American journal of obstetrics & gynecology MFM·2026

Same author

Association between post-COVID-19 neuropsychiatric symptoms and persistent glial activation in the limbic system: a TSPO PET study.

Journal of neurology·2026

Search research articles

Related Experiment Video

Updated: May 8, 2026

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Modeling Multiple Sclerosis in the Two Sexes: MOG_35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

[Multiple sclerosis and pregnancy].

Jori Ruuskanen¹, Heli Malm, Laura Airas

¹Turun yliopistollinen keskussairaala, neurotoimialue ja Medbase Oy, Turku

Duodecim; Laaketieteellinen Aikakauskirja

|August 22, 2013

Summary

This summary is machine-generated.

Multiple sclerosis symptoms often decrease during pregnancy but increase postpartum. Interferon-beta and glatiramer are likely safe for pregnant multiple sclerosis patients, unlike fingolimod, which requires discontinuation before conception.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Related Experiment Videos

Last Updated: May 8, 2026

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Modeling Multiple Sclerosis in the Two Sexes: MOG_35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Area of Science:

Neurology
Immunology
Reproductive Medicine

Context:

Multiple sclerosis (MS) management during pregnancy presents unique challenges.
MS activity typically decreases during gestation but rebounds postpartum.
Established immunomodulatory therapies have a long-standing safety record in pregnancy.

Purpose:

To review the safety of immunomodulatory drugs for multiple sclerosis during pregnancy.
To provide guidance on the use of interferon-beta, glatiramer, and fingolimod in women with MS planning conception.

Summary:

Interferon-beta and glatiramer have been used for over 15 years in MS patients with no noted adverse fetal effects.
These therapies are considered likely safe for use until pregnancy initiation.
Fingolimod is contraindicated due to suspected teratogenicity, requiring cessation two months prior to conception.

Impact:

Informs clinical practice regarding safe and unsafe MS treatments for women of childbearing potential.
Aids in family planning for individuals with multiple sclerosis.
Contributes to improved maternal and fetal outcomes in pregnancies affected by multiple sclerosis.